Renovorx Inc (RNXT) Stock Price, Quote & News

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 284 4433

Fax: 650 397 4433

Website: renovorx.com

Address:

2570 West El Camino Real, Suite 320, Mountain View, United States

Rnxtsavior Mar. 19 at 2:08 PM

$RNXT Told you.. they always play the same games.. under a dollar by lunch.. over a dollar streak ends today.

1 · Reply

Rnxtsavior Mar. 19 at 12:00 PM

$RNXT So looks like they will do a little low volume fake pump up this pre market.... usually means a day of selling.. under a buck close today????

1 · Reply

GordoHLYK13 Mar. 18 at 11:08 PM

$CXAI $GXAI $RNXT $TAOP $CXAI Bullish Edge • Google Partnership: CXAI is co-developing AI infrastructure directly with Google Cloud, a level of institutional backing that $700K-float micro-caps simply lack. • Gartner Validation: Recognized by Gartner as a leader in a sector reaching $77 billion in 2026, CXAI is shifting from "experimentation to execution" for global firms. • 180-Day Runway: The Nasdaq extension until September 7, 2026, provides a critical stability window to capitalize on their recent 112% ARR growth and massive financial sector deployments.

1 · Reply

victory369 Mar. 18 at 6:34 PM

$RNXT Let’s go 😁💥🚀

0 · Reply

Wolfietrader Mar. 18 at 4:51 PM

$RNXT I am amazed this isn’t 10% lower

2 · Reply

BA777 Mar. 18 at 2:00 PM

$RNXT

1 · Reply

enzomassimi Mar. 18 at 1:10 PM

$RNXT BUY FAST!

0 · Reply

Wolfietrader Mar. 18 at 1:07 PM

$RNXT common shares increasing 10.6m. I hope they spend it wisely and not on new executive positions that don’t pay off

0 · Reply

Nataina Mar. 18 at 12:37 PM

$RNXT why down ?

1 · Reply

Stock_Catcher Mar. 18 at 12:35 PM

$RNXT RenovoRx Announces $10 Million at Market Private Placement

0 · Reply

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

Mar 18, 2026, 8:35 AM EDT - 3 days ago

RenovoRx Announces $10 Million at Market Private Placement

Feb 27, 2026, 8:30 AM EST - 22 days ago

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Feb 26, 2026, 8:30 AM EST - 23 days ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

Feb 10, 2026, 8:30 AM EST - 5 weeks ago

RenovoRx Establishes RenovoCath® Medical Advisory Board

Feb 5, 2026, 8:30 AM EST - 6 weeks ago

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Feb 4, 2026, 8:30 AM EST - 6 weeks ago

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Jan 28, 2026, 8:30 AM EST - 7 weeks ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 20, 2026, 8:30 AM EST - 2 months ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 14, 2026, 8:30 AM EST - 2 months ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 8, 2026, 8:30 AM EST - 2 months ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Dec 11, 2025, 8:30 AM EST - 3 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 1, 2025, 8:30 AM EST - 3 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Nov 19, 2025, 8:30 AM EST - 4 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 13, 2025, 4:05 PM EST - 4 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 6, 2025, 8:30 AM EST - 4 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 4, 2025, 8:30 AM EST - 4 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Oct 27, 2025, 8:30 AM EDT - 5 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 9, 2025, 8:30 AM EDT - 5 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Sep 25, 2025, 8:30 AM EDT - 6 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 11, 2025, 8:30 AM EDT - 6 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Aug 20, 2025, 8:30 AM EDT - 7 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 14, 2025, 4:05 PM EDT - 7 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 6, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Jul 28, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 14, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

May 15, 2025, 4:05 PM EDT - 11 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 8:30 AM EDT - 11 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 6, 2025, 8:30 AM EDT - 11 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 1, 2025, 8:30 AM EDT - 11 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 16, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 4, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Mar 28, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 26, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 20, 2025, 8:00 AM EDT - 1 year ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 19, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Feb 26, 2025, 8:00 AM EST - 1 year ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 13, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 11, 2025, 7:00 AM EST - 1 year ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 1 year ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 4:05 PM EST - 1 year ago

RenovoRx Announces Proposed Public Offering

Jan 27, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Rnxtsavior Mar. 19 at 2:08 PM

$RNXT Told you.. they always play the same games.. under a dollar by lunch.. over a dollar streak ends today.

1 · Reply

Rnxtsavior Mar. 19 at 12:00 PM

$RNXT So looks like they will do a little low volume fake pump up this pre market.... usually means a day of selling.. under a buck close today????

1 · Reply

GordoHLYK13 Mar. 18 at 11:08 PM

1 · Reply

victory369 Mar. 18 at 6:34 PM

$RNXT Let’s go 😁💥🚀

0 · Reply

Wolfietrader Mar. 18 at 4:51 PM

$RNXT I am amazed this isn’t 10% lower

2 · Reply

BA777 Mar. 18 at 2:00 PM

$RNXT

1 · Reply

enzomassimi Mar. 18 at 1:10 PM

$RNXT BUY FAST!

0 · Reply

Wolfietrader Mar. 18 at 1:07 PM

$RNXT common shares increasing 10.6m. I hope they spend it wisely and not on new executive positions that don’t pay off

0 · Reply

Nataina Mar. 18 at 12:37 PM

$RNXT why down ?

1 · Reply

Stock_Catcher Mar. 18 at 12:35 PM

$RNXT RenovoRx Announces $10 Million at Market Private Placement

0 · Reply

King68 Mar. 17 at 1:27 PM

$RNXT looking good to me

0 · Reply

JB_Research Mar. 16 at 9:03 PM

$RNXT CEO on building a MedTech company... https://www.youtube.com/watch?v=WlcaUOh9gJM

0 · Reply

Wolfietrader Mar. 16 at 6:31 PM

$RNXT what the?

1 · Reply

Rnxtsavior Mar. 16 at 1:23 PM

$RNXT slight rise pre market.. means will sell off trading hours.. so ridiculous.. SCAM

2 · Reply

StockDog2014 Mar. 12 at 7:33 PM

$RNXT sideways action. Tapping out. Good luck

0 · Reply

Purple_Tip_Capital Mar. 12 at 4:01 PM

$RNXT omg it moved up .02!! 🙌🙌

1 · Reply

Rnxtsavior Mar. 12 at 10:29 AM

$RNXT bid is .4568 sign of thing to come? I think so. Says 0.00 for the price..lol.. going there too!

0 · Reply

Wolfietrader Mar. 11 at 11:30 PM

$RNXT if no news was truly good news this would be at $100. I think they are out of gas. The company hired all these people but they can’t push this boulder up the hill.

0 · Reply

Purple_Tip_Capital Mar. 11 at 3:31 PM

$RNXT pinned with no buyers. We are COOKED. Sadly, it appears RNXT savior was right about this stock. She going to bleed out into a R/S.

1 · Reply

Wolfietrader Mar. 10 at 7:28 PM

$RNXT stock is walking in circles.

0 · Reply

biokvint Mar. 10 at 5:18 PM

$RNXT Failed to meet NASDAQ continued listing reqyirement. After it meets the requirement, it will go up not until then. Not a good time to buy now.

1 · Reply

StockDog2014 Mar. 9 at 2:27 PM

$RNXT in for a pump, short leash though

0 · Reply

Market Cap	37.75M
Revenue (ttm)	40,000.00
Net Income (ttm)	-8.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-22,025.00%
Debt to Equity Ratio	0.00

Volume	276,500
Avg Vol	304,506
Day's Range	N/A - N/A
Shares Out	36.65M
Stochastic %K	72%
Beta	1.34
Analysts	Strong Sell
Price Target	$6.75